Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
Biostrata Ltd on behalf of Thermo
FOCUS DIAGNOSTICS, INC.

Methylation-Based Biomarker Indicates Chemo Resistance of Colorectal Cancer

By Labmedica International staff writers
Posted on 02 Feb 2012
Hypermethylation of the TFAP2E gene was correlated with nonresponsiveness of colorectal cancer to a commonly used chemotherapeutic agent.

In a study involving more than 200 patients in four independent cohorts, Prof. Ebert at the University of Heidelberg (Germany) and his team demonstrated that hypermethylation of the TFAP2E gene was correlated with nonresponsiveness of colorectal cancer to the commonly used chemotherapeutic agent 5-fluorouracil (5-FU). The study was reported in the January 2012 edition of the New England Journal of Medicine.

Using a combination of data from cancer cell lines and patient samples, the authors demonstrated that this effect was potentially mediated through up-regulation of the DKK4 gene, previously implicated in 5-FU resistance. Resistance to treatment was observed with 5-FU based chemotherapy or 5-FU chemotherapy combined with radiation, indicating that TFAP2E methylation may be a valuable biomarker for response prediction in either setting.

The study demonstrates the growing role that biomarkers can play in the management of cancer and other diseases. Prof. Ebert commented: “In practical terms, we believe this study demonstrates the potential that novel DNA methylation biomarkers may have in improving the selection of therapies for this deadly disease. A prospective validation of the marker is, however, still required.”

Epigenomics AG (Berlin, Germany and Seattle, WA, USA) scientists believe that the study demonstrates the potential of TFAP2E and other biomarkers identified in Epigenomics’ DNA methylation discovery pipeline in supporting clinical decision making.

Epigenomics’ lead product, Epi proColon, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the United States.

Related Links:

University of Heidelberg
Epigenomics AG



EUROIMMUN AG
CELLAVISION AB
KARL HECHT GMBH & CO KG
WATERS CORPORATION

Channels

Clinical Chemistry

view channel
Image: The Avance III 600 spectrometer for proton nuclear magnetic resonance analysis (Photo courtesy of Bruker).

New Blood Test Can Predict Future Breast Cancer

The analysis of a blood sample could predict if a woman will get breast cancer within two to five years which could create a paradigm shift in early diagnosis of this malignant neoplasm as well as other diseases.... Read more

Hematology

view channel
Image: QuantiTect Reverse Transcription Kit (Photo courtesy of Qiagen).

Independent Prognostic Factor for Acute Myeloid Leukemia Discovered

Acute myeloid leukemia (AML) is a clonal disorder involving a hierarchy of leukemic cells, and with investigations of the mechanism of AML, many epigenetically-regulated genes have been approved as new... Read more

Industry News

view channel

Main Factors Driving Revenue Growth in Clinical Chemistry Identified

According to a report by Kalorama Information (New York, NY, USA), overall growth in the clinical chemistry market will be modest, driven mainly by new tests and demographic changes, including an aging population and increasing number of people at risk of cardiovascular disease, such as those with hypertension, diabetes... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.